Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1987 2
1994 1
1996 2
1998 1
2000 1
2001 2
2002 3
2005 3
2006 2
2008 3
2009 1
2011 2
2012 1
2013 2
2014 1
2021 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2013 Feb;88(2):141-50. doi: 10.1002/ajh.23384. Am J Hematol. 2013. PMID: 23349007 Free article. Review.
Differential diagnosis of myelofibrosis should include chronic myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. ...Splenectomy and low-dose radiotherapy are used for drug-refractory …
Differential diagnosis of myelofibrosis should include chronic myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic …
Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2011 Dec;86(12):1017-26. doi: 10.1002/ajh.22210. Am J Hematol. 2011. PMID: 22086865 Free article. Review.
Differential diagnosis of myelofibrosis should include chronic myelogenous leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. ...Allogeneic stem cell transplantation or experimental drug therapy …
Differential diagnosis of myelofibrosis should include chronic myelogenous leukemia, myelodysplastic syndromes, chronic myelomonoc …
Radioimmunoconjugates in acute leukemia treatment: the future is radiant.
Kotzerke J, Bunjes D, Scheinberg DA. Kotzerke J, et al. Bone Marrow Transplant. 2005 Dec;36(12):1021-6. doi: 10.1038/sj.bmt.1705182. Bone Marrow Transplant. 2005. PMID: 16247432 Review.
Targeted radiotherapy of the bone marrow using radiolabeled monoclonal antibodies is a therapeutic approach of considerable potential for the treatment of acute leukemia in addition to or as a substitute for total body irradiation. ...It appears to reduce the …
Targeted radiotherapy of the bone marrow using radiolabeled monoclonal antibodies is a therapeutic approach of considerable potential …
Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2014 Sep;89(9):915-25. doi: 10.1002/ajh.23703. Am J Hematol. 2014. PMID: 25124313 Free article.
Prefibrotic PMF mimics ET in its presentation and the distinction, enabled by careful bone marrow morphological examination, is prognostically relevant. Differential diagnosis also includes chronic myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic …
Prefibrotic PMF mimics ET in its presentation and the distinction, enabled by careful bone marrow morphological examination, is prognostical …
New agents for the treatment of acute myelogenous leukemia: focus on topotecan and retinoids.
Estey EH. Estey EH. Leukemia. 1998 Sep;12 Suppl 1:S13-5. Leukemia. 1998. PMID: 9777888 Review.
Topotecan and retinoids are among the most promising agents being evaluated for the treatment of acute myelogenous leukemia (AML), refractory anemia with excess blasts (RAEB), and refractory anemia with excess blasts in transformation (RAEB-t). ...Topo …
Topotecan and retinoids are among the most promising agents being evaluated for the treatment of acute myelogenous leukemia (A …
A novel intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of relapsed/refractory acute myeloid leukemia.
Sun Y, Zhang J, Long B, Zhang X, Wen R, He Y, Li X. Sun Y, et al. Neoplasma. 2021 Nov;68(6):1351-1358. doi: 10.4149/neo_2021_210426N573. Epub 2021 Oct 10. Neoplasma. 2021. PMID: 34641697
We conducted a prospective study to evaluate the efficacy and safety of cladribine, cytarabine, mitoxantrone, and granulocyte colony-stimulating factor (CLAG-M) regimen combined with busulfan and cyclophosphamide (BuCy) as new intensive conditioning before allogeneic hematopoieti …
We conducted a prospective study to evaluate the efficacy and safety of cladribine, cytarabine, mitoxantrone, and granulocyte colony-stimula …
Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia.
Voutsadakis IA. Voutsadakis IA. Anticancer Drugs. 2002 Aug;13(7):685-92. doi: 10.1097/00001813-200208000-00002. Anticancer Drugs. 2002. PMID: 12187324 Review.
In the beginning of 2000 it obtained US Food and Drug Administration approval for the treatment of refractory acute myeloid leukemia (AML) expressing CD33 in patients older than 60 years who are not candidates for other chemotherapy. ...A phase II study point …
In the beginning of 2000 it obtained US Food and Drug Administration approval for the treatment of refractory acute myeloid …
Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
Countouriotis A, Moore TB, Sakamoto KM. Countouriotis A, et al. Stem Cells. 2002;20(3):215-29. doi: 10.1634/stemcells.20-3-215. Stem Cells. 2002. PMID: 12004080 Review.
Conventional cytotoxic therapy of hematologic malignancies is often associated with significant morbidity. ...Rituximab, a chimeric anti-CD20 antibody, has shown response rates of approximately 50% with minimal toxicity in patients with refractory indolent lymphoma. …
Conventional cytotoxic therapy of hematologic malignancies is often associated with significant morbidity. ...Rituximab, a chimeric a …
New treatment approaches for myelodysplastic syndrome and secondary leukaemias.
De Witte T. De Witte T. Ann Oncol. 1994 May;5(5):401-8. doi: 10.1093/oxfordjournals.annonc.a058870. Ann Oncol. 1994. PMID: 8075047 Free article. Review.
All patients, including those without an excess of blasts, should be conditioned with bone marrow ablative therapy rather than an immune suppressive regime, such as cyclophosphamide alone. For the majority of patients there is no standard therapy other than appropri …
All patients, including those without an excess of blasts, should be conditioned with bone marrow ablative therapy rather than an imm …
Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.
Zhao L, Yang J, Chen M, Xiang X, Ma H, Niu T, Gong Y, Chen X, Liu J, Wu Y. Zhao L, et al. Ann Hematol. 2024 Apr;103(4):1197-1209. doi: 10.1007/s00277-024-05646-7. Epub 2024 Feb 8. Ann Hematol. 2024. PMID: 38329487
Venetoclax (VEN), a BCL-2 inhibitor, has transformed treatment strategies for elderly and unfit acute myeloid leukemia (AML) patients by significantly improving response rates and survival. ...This real-world study examined 162 newly diagnosed (ND) and 85 relapsed/ …
Venetoclax (VEN), a BCL-2 inhibitor, has transformed treatment strategies for elderly and unfit acute myeloid leukemia (AML) p …
28 results